Biohaven (BHVN) EBITDA (2021 - 2026)

Biohaven (BHVN) has 6 years of EBITDA data on file, last reported at -$130.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 41.13% year-over-year to -$130.4 million; the trailing twelve-month figure through Mar 2026 stood at -$654.2 million (up 29.15% YoY), and the FY2025 full-year result was -$745.4 million, up 15.79% from the prior year.
• EBITDA improved to -$130.4 million in Q1 2026, from -$142.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$67.6 million in Q3 2022 to a low of -$333.8 million in Q2 2024.
• A 5-year average of -$162.6 million and a median of -$169.4 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 319.42% in 2022 and soared 52.31% in 2023, its largest moves.
• Tracing BHVN's EBITDA over 5 years: stood at -$213.4 million in 2022, then climbed by 27.97% to -$153.7 million in 2023, then slipped by 23.56% to -$189.9 million in 2024, then increased by 24.85% to -$142.7 million in 2025, then climbed by 8.62% to -$130.4 million in 2026.
• Business Quant data shows BHVN's EBITDA at -$130.4 million in Q1 2026, -$142.7 million in Q4 2025, and -$169.4 million in Q3 2025.